Agilent Technologies, Inc. (NYSE:A) – Equities research analysts at SVB Leerink boosted their Q1 2022 earnings per share estimates for shares of Agilent Technologies in a research note issued on Monday, November 22nd. SVB Leerink analyst P. Souda now anticipates that the medical research company will earn $1.17 per share for the quarter, up from their previous forecast of $1.09. SVB Leerink currently has a “Outperform” rating and a $175.00 price target on the stock. SVB Leerink also issued estimates for Agilent Technologies’ Q3 2022 earnings at $1.22 EPS and Q4 2022 earnings at $1.28 EPS.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 22nd. The medical research company reported $1.21 EPS for the quarter, beating the consensus estimate of $1.17 by $0.04. Agilent Technologies had a return on equity of 26.12% and a net margin of 16.12%. The company had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.66 billion. During the same quarter last year, the company posted $0.98 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year.
Shares of A stock opened at $152.97 on Thursday. Agilent Technologies has a 12 month low of $112.47 and a 12 month high of $179.57. The company has a quick ratio of 1.63, a current ratio of 2.11 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $159.22 and its two-hundred day moving average is $154.31. The company has a market cap of $46.31 billion, a PE ratio of 47.80, a price-to-earnings-growth ratio of 2.67 and a beta of 0.98.
Several large investors have recently made changes to their positions in A. Windward Capital Management Co. CA increased its holdings in shares of Agilent Technologies by 1.2% during the 2nd quarter. Windward Capital Management Co. CA now owns 5,598 shares of the medical research company’s stock worth $827,000 after acquiring an additional 68 shares during the last quarter. Savant Capital LLC grew its holdings in Agilent Technologies by 3.6% in the 2nd quarter. Savant Capital LLC now owns 1,939 shares of the medical research company’s stock valued at $287,000 after buying an additional 68 shares in the last quarter. Landsberg Bennett & Dubbaneh LLC grew its holdings in Agilent Technologies by 3.9% in the 3rd quarter. Landsberg Bennett & Dubbaneh LLC now owns 1,867 shares of the medical research company’s stock valued at $291,000 after buying an additional 70 shares in the last quarter. Sunbelt Securities Inc. grew its holdings in Agilent Technologies by 2.6% in the 2nd quarter. Sunbelt Securities Inc. now owns 2,769 shares of the medical research company’s stock valued at $412,000 after buying an additional 71 shares in the last quarter. Finally, MAI Capital Management grew its holdings in Agilent Technologies by 2.4% in the 2nd quarter. MAI Capital Management now owns 3,197 shares of the medical research company’s stock valued at $473,000 after buying an additional 74 shares in the last quarter.
In other Agilent Technologies news, SVP Padraig Mcdonnell sold 1,500 shares of Agilent Technologies stock in a transaction on Friday, November 19th. The stock was sold at an average price of $165.00, for a total transaction of $247,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 26th. Shareholders of record on Tuesday, January 4th will be issued a dividend of $0.21 per share. The ex-dividend date of this dividend is Monday, January 3rd. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.19. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.55%. Agilent Technologies’s dividend payout ratio (DPR) is presently 24.38%.
Agilent Technologies Company Profile
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
Featured Story: Overbought
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.